EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk
Speakers at EASD present divergent risk-benefit analyses for use of SGLT2 inhibitors in type 1 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment
Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes
Full results pr... Biopharmaceuticals, Endocrinology Boehringer Ingelheim, Eli Lilly, empagliflozin, EASE-2 study, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2018 Category: Pharmaceuticals Source Type: news
Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 4, 2018 Category: Research Source Type: news
Empa long-term survival benefit
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news
How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news
Empagliflozin Doesn't Up Risk of Bone Fractures
FRIDAY, July 20, 2018 -- Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care.
Sven Kohler, M.D., from Boehringer Ingelheim International in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2018 Category: Pharmaceuticals Source Type: news
Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 10, 2018 Category: Biotechnology Authors: Paul J. Gough Source Type: news
Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 10, 2018 Category: American Health Authors: Paul J. Gough Source Type: news
Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients
Eli Lilly& Co said on Monday that its drug Jardiance (empagliflozin), along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes, a population for which it is not presently approved.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Lilly's Jardiance meets main goal of two diabetes trials
(Reuters) - Eli Lilly& Co said on Monday that its drug Jardiance, along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Empagliflozin cost effective for T2D + CV disease in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news
Novo Nordisk oral diabetes drug outperforms Lilly rival
The company ' s oral diabetes drug semaglutide was found to be better at lowering blood sugar levels than Jardiance from Eli Lilly and Boehringer Ingelheim (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 29, 2018 Category: Pharmaceuticals Source Type: news
Novo Nordisk's oral diabetes drug beats Jardiance in study
LONDON (Reuters) - An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes. (Source: World Pharma News)
Source: World Pharma News - April 16, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
